ライフサイエンスコーパス: heregulin

1 3/ErbB2 chimeras confirm this dual effect of heregulin.

2 and the mechanism of oligomer disruption by heregulin.

3 rs are destabilized by binding of the ligand heregulin.

4 with HER2/NEU or its transactivating ligand HEREGULIN.

5 readily detected 2 min after the addition of heregulin.

6 er cell lines were screened for responses to heregulin.

7 ErbB2-overexpressing cells in the absence of heregulin.

8 rosine kinase in the presence and absence of heregulin.

9 fect of cucurbitacin I on Rac1 activation by heregulin.

10 failed to affect the activation of P-Rex1 by heregulin.

11 spholipase C (PLC)-gamma1 with HER2 than did heregulin.

12 ding the heterodimer ligands EGF/TGFalpha or heregulin.

13 ibited the lamellipodia formation induced by heregulin.

14 ed secretion of TGF-alpha, amphiregulin, and heregulin.

15 e inhibitor (EGFR TKI) resistance induced by heregulin.

16 prominent among these are the Neuregulins or Heregulins.

17 le defined medium containing an IGF1 analog, heregulin-1beta (a ligand for ERBB2/ERBB3), fibroblast g

18 Heregulin (6 nmol/L) induced tyrosine phosphorylation an

19 els of HER2 under epidermal growth factor or heregulin (a HER3 ligand) stimulation.

20 cer cells and, in particular, in response to heregulin, a growth factor that activates the Neu/ErbB2

21 In the present study, we examined whether heregulin, a HER3 ligand that is also overexpressed in a

22 Additionally, the ErbB ligand, heregulin, activates Brk kinase activity.

23 Heregulin activation of the endogenous receptor tyrosine

24 This indicated that autocrine heregulin activity was responsible for growth factor ind

25 human cells growing in nude mice to address heregulin activity.

26 n-binding growth factors, as well as that to heregulin alpha, heregulin beta, and hepatocyte growth f

27 , immediately following a mechanical injury, heregulin-alpha activates erbB2 in cells at the edge of

28 junctions between adjacent cells are opened, heregulin-alpha activates its receptor.

29 at in differentiated human airway epithelia, heregulin-alpha is present exclusively in the apical mem

30 Heregulin also induced colocalization of S1P(1) (promoti

31 cells, LMO4 transcripts were upregulated by heregulin, an activator of ErbB receptors that are known

32 strongly induced by the transforming ligand heregulin and complexes incorporated a number of additio

33 Higher levels of heregulin and ErbB2 activation were observed in the grow

34 ption in breast carcinoma cells treated with heregulin and this effect was inhibited by MTA1 knockdow

35 Although the combination of heregulin and troglitazone (HRG/TGZ) induced both apopto

36 It not only encodes the heregulins and other mitogenic ligands for the ERBB fami

37 ely produce both a ligand, the growth factor heregulin, and its receptors--erbB2, erbB3 and erbB4.

38 t signal was specific to ErbB3 activation by heregulin, and was not observed in response to epidermal

39 own of Ack1 or Src showed that Ack1 mediates heregulin- and Gas6-induced AR Tyr-267 phosphorylation,

40 Heregulins are a family of ligands for the ErbB3/ErbB4 r

41 The heregulins are a family of ligands with ability to induc

42 Heregulins are a group of growth factors that play diver

43 ntial display of mRNA that the growth factor heregulin beta 1 (HRG), a combinatorial ligand for human

44 4ICD and STAT5A colocalize within nuclei of heregulin beta 1 (HRG)-stimulated cells and both protein

45 factors, as well as that to heregulin alpha, heregulin beta, and hepatocyte growth factor.

46 nse of HCA-7 cells to the HER-3/HER-4 ligand heregulin beta-1 (HRGbeta-1).

47 ErbB3 binds heregulin beta-1 (HRGbeta1) and forms a heterodimer with

48 e to the peptide growth factors (IGF-1, EGF, heregulin-beta, and bFGF), and partially blocked the res

49 of increasing concentrations of IGF-1, EGF, heregulin-beta, bFGF, or estrogen under un-induced and i

50 In breast cancer cells, heregulin beta1 (HRG) causes a strong activation of Rac;

51 Heregulin beta1 (HRG), a combinatorial ligand for human

52 Heregulin beta1 (HRG), a combinatorial ligand for human

53 Heregulin beta1 (HRG), a combinatorial ligand for human

54 aused by fibroblast growth factor 1 (FGF-1), heregulin beta1 (HRGbeta1), and epidermal growth factor

55 an be induced by the highly malignant factor heregulin beta1 (HRGbeta1), which induces HSP expression

56 Both heregulin beta1 and estradiol could neither restore cdk1

57 GF) receptor family that can be activated by heregulin beta1 and heparin binding (HB)-EGF, is express

58 Heregulin beta1 induced phosphorylation of both HER3 and

59 Heregulin beta1 or estradiol abrogate antiestrogen effec

60 The polypeptide heregulin beta1 stimulated, and herceptin, the anti-ErbB

61 tronger chemotaxis and invasion responses to heregulin beta1.

62 ctivity during colon cancer cell invasion by heregulin-beta1 (HRG) and prostaglandin E2 (PGE2), we ha

63 Both EGF and heregulin-beta1 (HRG) induced EF-1alpha promoter activit

64 Heregulin-beta1 (HRG) promotes motility, scattering, and

65 pression in combination with the HER4 ligand heregulin-beta1 (HRG) resulted in apoptosis of BT20 cell

66 hiolated form of the HER3-binding peptide of heregulin-beta1 (HRG) with or without a 12- or 24 mer po

67 Heregulin-beta1 (HRG), a combinatorial ligand for human

68 Treatment of MCF-7 cells with 10(-9) M heregulin-beta1 (HRG-beta1) resulted in a rapid phosphor

69 ), insulin-like growth factor-I (IGF-I), and heregulin-beta1 (HRG-beta1), can modulate the expression

70 Heregulin-beta1 activates multiple signaling pathways in

71 Heregulin-beta1 also induced the expression of uPAR mRNA

72 Heregulin-beta1 also stimulated angiogenesis in a VEGF-d

73 Bmx stimulation in response to heregulin-beta1 and EGF was Src-dependent, and heregulin

74 on by growth factors, MMP-9 was activated by heregulin-beta1 as shown by zymography in both SKBr3 and

75 so associated with ErbB3 in LNCaP cells, and heregulin-beta1 enhanced this interaction and further st

76 els were still markedly decreased by EGF and heregulin-beta1 in LNCaP cells adapted to growth in andr

77 study was undertaken to explore the role of heregulin-beta1 in regulating uPA and uPAR in breast can

78 Both EGF and heregulin-beta1 induced expression of hnRNP K mRNA and p

79 The stimulation by heregulin-beta1 of breast cancer epithelial cells induce

80 The stimulation by heregulin-beta1 of noninvasive human breast cancer MCF-7

81 Heregulin-beta1 promotes the activation of p21-activated

82 hat activation of these kinases with EGF and heregulin-beta1 rapidly (within 8 hours) decreased expre

83 These results suggest that heregulin-beta1 regulates angiogenesis via up-regulation

84 These results suggest that heregulin-beta1 regulation of breast cancer cell invasio

85 reatment of these cells with the EGFR ligand heregulin-beta1 signals through the ERK and the phophati

86 regulin-beta1 and EGF was Src-dependent, and heregulin-beta1 stimulation of Bmx was also PI 3-kinase-

87 Furthermore, expression of the heregulin-beta1 transgene, HRG, in harderian tumors in m

88 CaP cells were markedly decreased by EGF and heregulin-beta1, and experiments with actinomycin D to b

89 VEGF expression are positively regulated by heregulin-beta1, we hypothesized that Pak1 regulates VEG

90 Heregulin-beta1, which binds human epidermal growth fact

91 tors that specifically inhibit each of these heregulin-beta1-activated pathways.

92 Heregulin-beta1-induced Ang-2 up-regulation is abrogated

93 iogenesis, our studies suggest that blocking heregulin-beta1-mediated activation of MMP-9 by inhibiti

94 kinase inhibitor SB203580 completely blocked heregulin-beta1-mediated activation of MMP-9.

95 We examined the pathways involved in heregulin-beta1-mediated MMP-9 activation using chemical

96 PI3-K inhibitor wortmannin had no effect on heregulin-beta1-mediated MMP-9 activation.

97 Herceptin, an anti-HER2 antibody inhibited heregulin-beta1-mediated stimulation of both VEGF expres

98 we found that WWP1 negatively regulates the heregulin-beta1-stimulated ErbB4 activity as measured by

99 Heregulin-beta1-stimulated signaling initiated the trans

100 id blocks NOTCH1 up-regulation by EGF and/or heregulin-beta1.

101 exposed to the EMT-inducing factors EGF and heregulin-beta1.

102 rom transcriptional upregulation of MMP-9 by heregulin-beta1.

103 s are involved in the activation of MMP-9 by heregulin-beta1.

104 both in the absence or presence of exogenous heregulin-beta1.

105 h factor (VEGF) as a gene product induced by heregulin-beta1.

106 activation in response to RTK stimulation by heregulin-beta1.

107 Although heregulin binding initiates cellular proliferation and d

108 Heregulin binding was prevented by RG7116 at concentrati

109 e kinase homo- and heterodimerizes following heregulin binding, which provokes increased levels of ty

110 Heregulin binds erbB receptors, and in our studies, prim

111 Transmembrane heregulin binds to cells expressing p180(HER-3), induces

112 erodimerization, inhibited growth induced by heregulin but not AP1510.

113 h factors in the mammary gland, we show that heregulin but not her2/neu, c-Myc or v-Ha-ras plays a ma

114 Heregulin, but not ID5, activated the c-Jun-NH2-terminal

115 Heregulin, but not ID5, induced the p85 subunit of phosp

116 The ErbB2/ErbB3 heregulin co-receptor has been shown to couple to phosph

117 The heregulin-dependent activation of Ran requires mTOR (mam

118 UM102 cells resulted in the acquisition of a heregulin-dependent antiproliferative response, associat

119 Only cells that expressed HER4 exhibited heregulin-dependent antiproliferative responses.

120 Ack1 knockdown inhibited heregulin-dependent AR tyrosine phosphorylation, AR repo

121 esults indicate that patritumab can overcome heregulin-dependent EGFR inhibitor resistance in NSCLC i

122 olutionary conserved tyrosine 1114 site in a heregulin-dependent manner, even in the presence of tamo

123 ouple to phosphoinositide (PI) 3-kinase in a heregulin-dependent manner.

124 culture and induced tumor regression in the heregulin-dependent MDA-MB-175 xenograft model.

125 BRCA1-positive MECs displayed heregulin-dependent mitotic delay; however, the isogenic

126 The role of HER2 in these heregulin-dependent responses was examined through elimi

127 Here, the heregulin-dependent translocation of Akt to the plasma m

128 kinase activity is stringently required for heregulin-dependent, but not 12-O-tetradecanoylphorbol-1

129 Heregulin destabilizes oligomeric complexes but not dime

130 AP1510, EGF, and heregulin each induced growth of MCF10A cells expressing

131 g the epidermal growth factor-like region of heregulin ectodomain for 3 months in vivo resulted in up

132 Human DOC4 and the heregulin-encoding genes map to different chromosomes an

133 and pharmacologic inhibition of JNK impaired heregulin-enhanced expression of BRCA1 and mitotic delay

134 atment of cells with EGF (ErbB1-specific) or heregulin (ErbB4-specific) resulted in a hierarchic tran

135 esistance was associated with an increase in heregulin expression and ErbB3 activation.

136 Patritumab sensitivity was associated with heregulin expression, which, when abolished, resulted in

137 which blocks phosphorylation of her2/neu by heregulin, failed to reduce NF-kappaB activation.

138 UB branching morphogens (i.e., pleiotrophin, heregulin, FGF1 and GDNF) were found to have a higher af

139 pathway involved in the survival function of heregulin, focusing on heregulin-induced changes in Akt

140 -4 cells with epidermal growth factor (EGF), heregulin, Gas6 (ligand binding to the Mer receptor tyro

141 nsforming growth factor-alpha, amphiregulin, heregulin, heparin binding EGF-like ligand).

142 for VEGF induction and tumor angiogenesis by heregulin-HER2 signaling and establish a novel mechanism

143 Heregulin/HER4-dependent mitotic delay was examined furt

144 th factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG) -mediated ErbB3 signaling and inducing E

145 Heregulin (HRG) belongs to a family of polypeptide growt

146 We show that the EGF-like domain of heregulin (hrg) binds to domains I and II of HER3, in co

147 s blocked by an antibody against HER-2 or by heregulin (HRG) depletion from the conditioned medium th

148 Stimulation of T47D cells with heregulin (HRG) induced the tyrosine phosphorylation of

149 Heregulin (HRG) is a member of the neuregulin family of

150 Heregulin (HRG) is an activator of the erbB2-, erbB3- an

151 We have previously shown that expression of heregulin (HRG) is closely correlated with breast cancer

152 studied the effects of ErbB-2 activation by heregulin (HRG) on BRCA1 function.

153 After binding of its ligand heregulin (HRG) or activation of protein kinase C (PKC)

154 The ErbB3/4 ligand heregulin (HRG) profoundly affects cell growth and diffe

155 The mechanisms through which heregulin (HRG) regulates the progression of breast canc

156 cells with epidermal growth factor (EGF) or heregulin (HRG) results in marked upregulation of MUC1-C

157 GF receptor HER-2 (erbB2) leads to amplified heregulin (HRG) signaling, promoting more aggressive bre

158 ression), but was significantly induced upon heregulin (HRG) stimulation.

159 phila S2 cells, binds the EGF-like domain of heregulin (hrg) with a K(d) of 1.9 nM as measured by sur

160 pha(v)beta(3) integrin and overexpression of Heregulin (HRG), a growth factor associated with breast

161 reast cancer cells exhibiting high levels of Heregulin (HRG), a growth factor closely associated with

162 In concert with these results, we show that heregulin (HRG), a ligand for ErbB receptors, activates

163 The growth factor heregulin (HRG), a ligand of ErbB3 and ErbB4 receptors,

164 ErbB-3 transmits the signals of its ligand, heregulin (HRG), are incompletely understood.

165 We now show that heregulin (HRG), but not EGF, stimulates p95ErbB2 phosph

166 Mice heterozygous (+/-) for either heregulin (HRG), ErbB2, or ErbB3 were created by gene ta

167 The growth factor heregulin (HRG), expressed in about 30% of breast cancer

168 tivation by epidermal growth factor (EGF) or heregulin (HRG), significantly improves prediction of ce

169 subset of the cell lines for Src-dependent, heregulin (HRG)-augmented, anchorage-dependent and indep

170 Heregulin (HRG)-induced cell responses are mediated by t

171 vestigate these mechanisms, we observed that heregulin (HRG)-mediated activation of HER2, or HER2 ove

172 (sErbB3), is a potent negative regulator of heregulin (HRG)-stimulated ErbB2, ErbB3, and ErbB4 activ

173 ely regulates crosstalk between ErbB3 ligand heregulin (HRG)-triggered signaling and the AR axis, aff

174 absence of its ligands, various isoforms of heregulin (hrg).

175 s can be increased with HER ligands, such as heregulin (HRG).

176 K, markedly upregulated the HER3/HER4 ligand heregulin (HRG).

177 crosequencing, the protein was identified as heregulin (HRG)alpha.

178 al, addition of the ErbB3/ErbB4 ligand alpha-heregulin (HRG; 1-100 ng/ml) inhibited secretory respons

179 actor deprivation was effectively blocked by heregulin in a wortmannin-sensitive manner.

180 and motility in response to the ErbB3 ligand heregulin in breast cancer cells.

181 nvestigate further the signaling pathway for heregulin in glial cells, BAD was overexpressed in C6 gl

182 ting pathways of G(2)/M delay, we noted that heregulin increased the expression of BRCA1 in a HER4-de

183 regulin 1 (or NRG1, hereafter referred to as heregulin) increased CXCR4 expression in breast cancer c

184 Concordantly, ID5, but not heregulin, increased PLC-gamma1 activity.

185 Based on these results, we propose that heregulin increases the expression of pro-invasive, pro-

186 In these cells, heregulin induced phosphorylation of BAD at Ser(136).

187 Heregulin induced sustained activation of P13-K signalin

188 ls and primary cultures of oligodendrocytes, heregulin induced time- and dose-dependent Akt phosphory

189 Dasatinib inhibited heregulin-induced Ack1 kinase activity and AR Tyr-267 ph

190 nd blocks epidermal growth factor (EGF)- and heregulin-induced activation of Rac GTPase, extracellula

191 ErbB3 that results in increased basal and/or heregulin-induced activation of receptors, and their dow

192 Heregulin-induced apoptosis could be blocked by inhibiti

193 In addition, dasatinib inhibited heregulin-induced AR-dependent reporter activity.

194 etreatment of SKBr3 cells with ID5 decreased heregulin-induced association of HER2 with HER3 as well

195 vels blocked a significant proportion of the heregulin-induced cell cycle progression in LNCaP cells.

196 tion of Pten was able to inhibit ErbB-2- and heregulin-induced cell cycle progression, as well as cyc

197 survival function of heregulin, focusing on heregulin-induced changes in Akt activity in cultured gl

198 The heregulin-induced cleavage of ErbB-4 could be blocked by

199 Although the heregulin-induced cleavage of ErbB-4 produced a fragment

200 Furthermore, EGF- and heregulin-induced cyclin D1 expression is dependent on p

201 Heregulin-induced differentiation could be eliminated by

202 lgi complex induce apoptosis and can prevent heregulin-induced differentiation.

203 nt acidification of endosomes were employed, heregulin-induced ErbB-4 cleavage was sensitive to metal

204 Dasatinib also inhibited heregulin-induced expression of endogenous AR target gen

205 kinase pathway in SKBr3 cells did not affect heregulin-induced G2-M-phase arrest, apoptosis, and diff

206 We demonstrate that heregulin-induced HER4 activity inhibits cell proliferat

207 with submicromolar affinities and to inhibit heregulin-induced interactions of erbB3 with different e

208 Finally, heregulin-induced migration of T47D cells requires p38 M

209 SphK1 was required for heregulin-induced migration, lamellipodia formation, act

210 ediated PI3-kinase signaling is critical for heregulin-induced motility, and therefore crucial for Er

211 Pharmacologic inhibition of heregulin-induced phosphoinositide-3-kinase/Akt (with LY

212 Heregulin-induced phosphorylation of BRCA1 was abrogated

213 These results suggest that heregulin induces NF-kappaB independent of her2/neu.

214 translated region of HIF-1alpha mRNA directs heregulin-inducible expression of a heterologous protein

215 Heregulin induction of PRL was also abrogated by transfe

216 which anti-p185HER2 antibody and the ligand heregulin inhibit tumor growth, we have investigated sev

217 While heregulin inhibits the growth of HER4-positive breast ca

218 Secreted heregulin is a 45-kDa growth factor with homology to epi

219 gamma-heregulin is characterized by the presence of a large N-

220 This study demonstrates that transmembrane heregulin is functionally active and suggest it is capab

221 at this unique N-terminal extension of gamma-heregulin is identical to the N-terminus of DOC4, a prod

222 t data suggest that the survival function of heregulin is mediated through the PI-3 kinase/Akt pathwa

223 Neuregulin (NRG; heregulin) is overexpressed in approximately 30% of brea

224 peptide extension that is not found in other heregulin isoforms.

225 reas sustained ERK activation in response to heregulin leads to adipocytic differentiation.

226 cells (Her-2 +/-) engineered to overexpress heregulin (MCF-7/HRG), a ligand for the Her-2/3/4 networ

227 Activation of ErbB2 was the result of heregulin mediated interaction with ErbB3 and generated

228 We have uncovered that heregulin-mediated ACK1 activation promoted ER activity

229 Heregulin-mediated activation of HER4 initiates receptor

230 inhibitor of I kappa B-kinase (IKK), blocked heregulin-mediated activation of NF-kappa B and cell pro

231 as the depletion of Pak1 interferes with the heregulin-mediated dephosphorylation of cofilin, the dep

232 athrin-coated pit formation, suggesting that heregulin-mediated ErbB-4 cleavage occurs subsequent to

233 c localization of utrophin occurs in part by heregulin-mediated extracellular signal-regulated kinase

234 These results suggest that heregulin-mediated growth inhibition in HER4-postive bre

235 Heregulin-mediated NF-kappaB activation correlated with

236 f ERK/MAP kinase or protein kinase C reduced heregulin-mediated NF-kappaB activation.

237 b, the tyrosine kinase inhibitor, suppressed heregulin-mediated p185(c-neu)/ErbB3 signaling to PRL.

238 Tryphostin AG1517, which inhibits heregulin-mediated phosphorylation of EGFR, her2/neu and

239 e related to focal adhesion kinase (FAK), in heregulin-mediated signal transduction in breast cancer

240 ilable on the contribution of Rho GTPases to heregulin-mediated signaling.

241 The amelioration of dystrophic phenotype by heregulin-mediated utrophin up-regulation offers a pharm

242 A is transcriptionally regulated in part by heregulin-mediated, extracellular signal-related kinase-

243 geted corrole noncovalently assembled with a heregulin-modified protein directed at the human epiderm

244 lin (EPR), heparin binding EGF (HB-EGF), and heregulin/neuregulin (HRG).

245 Blockade of ErbB2 activation by heregulin neutralizing antibodies and by AG879 resulted

246 Heregulin neutralizing antibody treatment of growth arre

247 the presence and absence of the ERBB3 ligand heregulin (NRG1).

248 onditions, as well as the in vivo effects of heregulin on human cells growing in nude mice to address

249 To evaluate the effects of heregulin on normal and malignant human breast and ovari

250 fragment is generated by cell treatment with heregulin or 12-O-tetradecanoylphorbol-13-acetate, the f

251 The data herein demonstrate that heregulin or betacellulin, but not EGF, promotes the rap

252 lts indicate that the activation of ErbB2 by heregulin or by its overexpression requires Grb2 to stim

253 reatment of LNCaP and LAPC-4 cells with EGF, heregulin or Gas6 induced AR phosphorylation at Tyr-267,

254 tment with EGF, IL-6 or bombesin, but not by heregulin or Gas6.

255 erentiation factor (NDF) mRNA (also known as heregulin, or HRG).

256 bination with EGFR TKIs to treat a subset of heregulin-overexpressing NSCLC patients.

257 s maintained in the presence of erlotinib in heregulin-overexpressing, EGFR-mutant NSCLC cells.

258 Furthermore, heregulin overexpression induced EGFR TKI resistance in

259 n overexpression or be transactivated by the heregulin polypeptide growth factor.

260 he Mr 46,000 isoform of SHC to HER2, whereas heregulin preferentially induced binding of the Mr 52,00

261 ing heregulin receptors are co-cultured with heregulin-producing cells, specific in vivo associations

262 In addition, when cells containing heregulin receptors are co-cultured with heregulin-produ

263 oyed and correlated this to their respective heregulin responses.

264 in several tumor cells lines the addition of heregulin results in the translocation of ErbB-4 to a de

265 mains unclear because its activating ligand, heregulin, results in either proliferation or differenti

266 We conclude that ID5 and heregulin signal via different pathways, although both a

267 clonal antibody 2C4 inhibited all aspects of heregulin signaling as well as anchorage-independent and

268 d ERK signaling as the primary transducer of heregulin signaling to PRL.

269 Heregulin stimulated c-Jun N-terminal kinase (JNK), and

270 Heregulin stimulated SphK1 activity only in FLNa-express

271 otein inhibition led to growth inhibition of heregulin-stimulated breast cancer cells, but not Erk1,2

272 inactivated following Grb2 downregulation in heregulin-stimulated breast cancer cells.

273 Similar to heregulin-stimulated cells, Grb2 inhibition also led to

274 tion of Pak1 decreases phospho-MLC levels in heregulin-stimulated cells, the depletion of Pak2 enhanc

275 Heregulin-stimulated HER2 activation induced Ack1 activa

276 Anti-ErbB2 monoclonal antibody 2C4 blocked heregulin-stimulated phosphorylation of ErbB2 and ErbB3;

277 ed here whether Grb2 protein plays a role in heregulin-stimulated proliferation.

278 Furthermore, inhibition of heregulin-stimulated Src kinase activity was markedly di

279 B-2 is directly related to the inhibition of heregulin-stimulated Src kinase activity.

280 trast to other inducers of HIF-1 expression, heregulin stimulation does not affect the half-life of H

281 esponse to epidermal growth factor (EGF) and heregulin stimulation in colon carcinoma cells.

282 Here, heregulin stimulation is shown to markedly upregulate ki

283 uced by overexpression in mouse 3T3 cells or heregulin stimulation of human MCF-7 breast cancer cells

284 Heregulin stimulation results in receptor phosphorylatio

285 ogen-responsive enhancers after androgen and heregulin stimulation.

286 We show that heregulin-stimulation induces trafficking of phosphoryla

287 In the absence of heregulin, the ectopic expression of the constitutively

288 Since Akt can also be activated by heregulin, the effects of Grb2 inhibition on Akt were ex

289 tivation of p185(c-neu)/ErbB3 signaling with heregulin, the ErbB3 ligand, in rat lacto-somatotroph (G

290 e to breast carcinoma invasion stimulated by heregulin, these roles are mediated by distinct signalin

291 We tested the ability of heregulin to improve the dystrophic phenotype in the mdx

292 ated receptor agonist, acted in synergy with heregulin to induce massive cell death in breast cancer

293 ated and associated with PI3K activity after heregulin treatment and that Gab1 and Gab2, but not ErbB

294 ly lack mesenchyme formation, are rescued by heregulin treatment, which restores phosphorylation of E

295 growth factor treatment, but decreased under heregulin treatment.

296 iologic activity of plasma membrane-anchored heregulin was evaluated in human breast cells.

297 Heregulin was originally detected in the conditioned med

298 Heregulin was shown to promote the proteolytic cleavage

299 Notably, heregulin was upregulated in tissue samples from an NSCL

300 7), made resistant to gefitinib by exogenous heregulin, was resensitized by MM-121.